Drugs / Felmetatug Vedotin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05194072 | Jan 2022 → May 2025 | adenoid cystic carcinoma, cholangiocarcinoma, endometrium neoplasm, fallopian tube neoplasm +6 | Pfizer | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-02-29 | Pfizer | Results Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth pfizer.com ↗
During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin. |
All press releases naming this drug 1 release
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Felmetatug Vedotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05194072 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068249 ↗ |
| Route | Intravenous | “Given into the vein (IV; intravenously)” NCT05194072 ↗ |